Atlas Trials

A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC

Clinical trial NCT05182944 · RECRUITING

Trial details

NCT number
NCT05182944
Sponsor
The First Affiliated Hospital of Zhengzhou University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Esophageal Cancer
Start date
2022-01-15
Primary completion
2024-01-15
Enrollment
130

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.